Option chain shows key data for Medicenna Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Medicenna Therapeutics.

Medicenna Therapeutics (OTC:MDNAF) Stock, Option Chain

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Penny Stocks

MDNAF

TSX:MDNA


  By David Bautz, PhD

TSX:MDNA.TO | OTC:MDNAF

READ THE FULL MDNA.TO RESEARCH REPORT

MDNA.TO: Data on MDNA55 and MDNA11 to be Presented at ASCO 2020…

Biotech

Long Ideas

News

Short Ideas

Emerging Markets

Specialty ETFs

Eurozone

Health Care

Global

Markets

Trading Ideas

ETFs

General

ADRNY

AXAHY

CYDY

DANOY

EXPGY

FNMA

GAXY

GBTC

HEINY

IMBBY

IPIX

JBSAY

KBLB

RHHBY

TOMDF

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

The COVID-19 pandemic has led to dramatic changes in market behavior, as traders and investors try to grapple with the short-term and long-term implications of a pandemic.

The Spread of COVID-19 Has Caused Massive Volume Spikes In Securities On OTC Markets

MDNA.TO: Encouraging MDNA19 Data in Non-Human Primates; Financing Funds Company Through End of 2022…

MEDICENNA THERA CORP by Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp

Warner Music Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) reported downbeat fiscal fourth-quarter 2024 <a href="https://www.benzinga.com/quote/WMG/earnings">earnings on Thursday</a>.
GAAP EPS of 8 cents missed the analyst consensus estimate of 27 cents. Revenue grew 2.8% year-on-year to $1.63 billion, beating the analyst consensus estimate of $1.59 billion.
Recorded Music revenue grew by 4.0% Y/Y at $1.34 billion in the quarter. Music Publishing revenue decreased by 1.0% Y/Y to $295 million. Digital revenue remained flat Y/Y at $1.07 billion.
Adjusted OIBDA increased by 11.4% compared to the previous year, reaching $353 million, and the margin improved by 170 basis points to 21.7%, driven by strong operating performance and savings from the company's restructuring plans.
&#8220;Our performance this quarter and this year demonstrated our strength and adaptability in a thriving, fast-moving market,&#8221; said Robert Kyncl, CEO, Warner Music Group. &#8220;We continue to evolve WMG, based on the principle that simplicity and focus drive higher intensity and global impact. This is enhancing our ability to attract original artists and songwriters at all stages of their careers, helping them realize their musical visions, and grow passionate, loyal fanbases.&#8221;
Warner Music shares gained 2.7% to trade at $32.01 on Friday.
These analysts made changes to their price targets on Warner Music following earnings announcement.
<ul>
<li>Barclays analyst Kannan Venkateshwar maintained Warner Music with an Equal-Weight rating and lowered the price target from $32 to $31.</li>
<li>JP Morgan analyst David Karnovsky maintained the stock with an Overweight and lowered the price target from $41 to $40.</li>
<li>Guggenheim analyst Michael Morris reiterated Warner Music with a Buy and maintained a $44 price target.</li>
</ul>
Considering buying WMG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="546" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22132400/image-253-1024x546.png" alt="" class="wp-image-661524" style="width:662px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22132400/image-253-1024x546.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22132400/image-253-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22132400/image-253-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22132400/image-253.png 1206w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Earnings

Price Target

Analyst Ratings

These Analysts Cut Their Forecasts On Warner Music Following Q4 Earnings

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining by more than 250 points on Friday.
The Dow traded up 0.59% to 44,128.84 while the NASDAQ rose 0.08% to 18,986.80. The S&amp;P 500 also rose, gaining, 0.28% to 5,965.15.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1.5% on Friday.
In trading on Friday, communication services shares fell by 0.6%.
Top Headline
Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) reported better-than-expected third-quarter EPS results.
The company said it sees FY25 earnings of $6.10 to $6.17 per share
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) shares shot up 16% to $109.17 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Shares of Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) got a boost, surging 19% to $30.26 following upbeat earnings.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 45% to $16.00 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 55% to $6.11 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 43% to $0.1390 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 41% to $0.1164 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $71.16 while gold traded up 1.1% at $2,704.00.
Silver traded up 1.1% to $31.275 on Friday, while copper fell 0.8% to $4.0940.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.12%, Germany's DAX gained 0.77% and France's CAC 40 rose 0.46%. Spain's IBEX 35 Index rose 0.16%, while London's FTSE 100 gained 1.35%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Equities

Commodities

Intraday Update

AMIX

APTO

CETX

ESTC

MATW

REPL

ROST

Crude Oil Gains Over 1%; Ross Stores Earnings Top Views

Robert F. Kennedy Jr. is a vocal opponent of artificial food dyes, blaming them in part for the &#8220;chronic disease epidemic" in America. He may get the opportunity to bring major changes to the U.S. food industry under the<a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction"> incoming Trump administration.</a>&nbsp;
What To Know: President-elect Donald Trump has named Kennedy as his pick to lead the department of Health and Human Services (HHS). If confirmed by the Senate, Kennedy would oversee the Food and Drug Administration, among other federal health agencies, and may be able to effect policy changes that align with his views, which have run counter to programs widely viewed by the public health community as successes, such as water fluoridation and vaccines. 
Read Next: <a href="https://www.benzinga.com/news/global/24/11/42101365/indian-billionaire-one-of-the-worlds-richest-men-indicted-for-alleged-250-million-bribery-scheme">Indian Billionaire, One Of The World&#8217;s Richest Men, Indicted For Alleged $250 Million Bribery Scheme</a>
Kennedy has criticized the use of artificial dyes in popular cereals, snacks and beverages and noted that some dyes, like Red Dye No. 3, are banned in Europe and California due to potential health risks. Kennedy argues the U.S. food system allows many additives that are restricted in other countries to the detriment of the public's health. 
"We are betraying our children by letting these industries poison them," Kennedy said at a Trump campaign rally Nov. 2.
The potential HHS secretary has often targeted breakfast cereals in particular due to their popularity with children. 
"They get brighter colors in Froot Loops, but it's literally poisoning our kids," Kennedy told Fox News in September.&nbsp;
Froot Loops maker Kellogg said in 2015 that it was working to remove artificial colors and flavors from its branded cereals by the end of 2018, <a href="https://www.wsj.com/business/how-froot-loops-landed-at-the-center-of-u-s-food-politics-a5074e63">according</a> to the Wall Street Journal.  WK Kellogg Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) still sells cereal that contains the ingredients.
"The first thing I'd do isn't going to cost you anything because I'm just gonna tell the cereal companies: Take all the dyes out of their food," Kennedy said in October.
Kennedy's potential new role as the country's top health official has caught the attention of other food industry giants like General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>). The mega-manufacturer of processed foods released a statement after Trump announced Kennedy as his choice for the position. 
"Because this is always an evolving space, we work in close partnership with policymakers on this issue," General Mills said in the statement. "We will engage with federal regulators as they consider any additional changes they may propose."
Why It Matters: Trump has said <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">he is ready</a> to let Kennedy "go wild on health" and he could &#8220;do pretty much what he wants&#8221; in his administration. In his announcement of his intent to nominate Kennedy as secretary of HHS, Trump said he expects him to "end the chronic disease epidemic , and to Make America Great and Healthy Again!"
"Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation and disinformation when it comes to public health," Trump's announcement stated.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a></li>
</ul>
Image: Shutterstock.

Government

Regulations

Politics

Kennedy's War On Food Dyes Could Be Coming To Your Breakfast Table

It was big news earlier this year when Warren Buffett revealed he's no longer planning to leave his vast fortune to the Gates Foundation after his death. Instead, his billions will go to a trust <a href="https://www.benzinga.com/startups/24/11/41866296/with-warren-buffett-donating-99-of-his-fortune-whats-left-for-his-three-children-well-its-complicated">managed by his three children</a>. For a man who once described <a href="https://www.benzinga.com/personal-finance/24/11/41882910/bill-gates-shares-the-best-investment-for-getting-rich-if-youre-earning-100000-or-less-but-wall-street-might-not-agree">Bill and Melinda Gates</a> as "the perfect solution" for dispersing his wealth, this marked a seismic shift in philanthropy.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
</ul>
In a 2008 Fortune profile, Buffett was clear in his admiration for Melinda, saying, "He's [Bill] smart as hell. But in terms of seeing the whole picture, she's smarter." He also referred to her as a "longtime friend." Buffett continued praising Melinda, saying, "I very much admire what she is doing for women around here and around the world."
Only weeks after the Gateses announced their divorce, Buffett resigned as a trustee of the foundation. As reported by The New York Times in a 2021 article, Buffett released a statement saying: "For years I have been a trustee – an inactive trustee at that – of only one recipient of my funds, the Bill and Melinda Gates Foundation. I am now resigning from that post, just as I have done at all corporate boards other than Berkshire's."
Warren Buffett may think Bill Gates is "smart as hell," but even he admitted in his Fortune profile, "Would I have given the Gates Foundation my fortune if Melinda weren't in the picture? That's a great question. And the answer is, I'm not sure."
See Also: <a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a>
The Buffett connection looms large in the October 2024 Vanity Fair interview, where Melinda discusses her life after divorce, the challenges of being a woman in philanthropy and her legacy. In classic Melinda style, she doesn't shy away from tough truths. She noted her decades of joint philanthropic work with Bill: "If I went into a president or prime minister's office and I was with my ex-husband, they would turn to him first. Unless I interrupted the conversation, they could have kept going for the whole meeting."
This wasn't just frustrating – it was telling. "Why would they assume I knew less than him about philanthropy when we had been doing it together for almost 25 years?" she asked. "That, really, was sexism."
Her willingness to call out these dynamics – and challenge them – is part of what makes her so effective. Melinda's journey from Microsoft marketing manager to one of the most powerful women in philanthropy hasn't been without its share of roadblocks. As she told Vanity Fair, during the early years of the foundation, she didn't understand the major role that gender played. She added, "But things just kept coming up for women – contraceptives or their health or what they wanted – that it started to make me realize we were making a mistake."
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
It's this insight that shaped the Gates Foundation's focus on global health and education, with a specific lens on empowering women and girls. From ensuring access to contraceptives to fighting preventable diseases, Melinda's fingerprints are all over the foundation's most impactful initiatives.
But what happens when Buffett's billions are no longer <a href="https://www.benzinga.com/personal-finance/24/10/41198368/warren-buffetts-son-who-famously-cashed-in-his-90-000-inheritance-at-19-spends-millions-in-buffe">flowing to the foundation</a>? That's a question no one seems to have a clear answer for yet. Melinda, for her part, seems more than ready to <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">embrace the challenge</a> as she continues to carve out her own space in the philanthropic world.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Image via Wikimedia Commons/ Flickr

Warren Buffett Thinks Bill Gates Is 'Smart As Hell' – But Says His Ex-Wife Melinda Is Smarter 'In Terms Of Seeing The Whole Picture'

Grand Theft Auto fans had high hopes for today, Nov. 22, anticipating an announcement for GTA 6's Trailer 2 <a href="https://www.benzinga.com/general/gaming/24/11/41884190/did-rockstar-drop-gta-6-trailer-hint-fans-spot-moon-clue-pointing-to-nov-22">based on a quirky "moon theory."</a>
Instead, they have been met with silence so far (as of publication), leaving the community frustrated and speculating about Rockstar's next move.
<h1 class="wp-block-heading">What Is GTA 6&#8217;s Moon Theory?</h1>
The moon theory traces back to 2023 when Rockstar released an image in GTA Online featuring the moon in a Waning Gibbous phase. That phase coincided with the announcement date for the first GTA 6 trailer two months later.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/42141838/elden-ring-creator-hidetaka-miyazaki-teases-various-new-projects-in-development">Elden Ring Creator Hidetaka Miyazaki Teases &#8216;Various New Projects&#8217; In Development</a>
When Rockstar released another image earlier this month showing the same moon phase, fans believed history would repeat itself. 
November 22 marked the final day of the current Waning Gibbous phase and fans were convinced Rockstar would either release the trailer or announce its release date.
But today, fans were met with no updates from Rockstar or <a href="https://www.benzinga.com/news/earnings/24/11/41818430/take-two-earnings-show-gta-6-on-track-for-2025-ceo-vows-no-huge-release-overlap">its parent company, Take-Two Interactive Software Inc </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>), which typically makes announcements around 9 am ET.
<figure class="wp-block-embed is-type-rich is-provider-reddit wp-block-embed-reddit"> 
<div class="wp-block-embed__wrapper">
<blockquote class="reddit-embed-bq" style="height:500px" ><a href="https://www.reddit.com/r/GTA6/comments/1gx7zps/the_community_for_the_past_2_weeks/">The community for the past 2 weeks:</a> by<a href="https://www.reddit.com/user/DaVoiceOfTruth/">u/DaVoiceOfTruth</a> in<a href="https://www.reddit.com/r/GTA6/">GTA6</a></blockquote>
<script async src="https://embed.reddit.com/widgets.js" charset="UTF-8"></script></div>
</figure>
<h1 class="wp-block-heading">A Long Wait For New Info</h1>
It's been nearly a year since Rockstar unveiled the first GTA 6 trailer, confirming a Vice City setting and breaking the internet in the process. Since then, fans have been left in the dark, with no follow-up announcements or new details.
Take-Two has maintained a Fall 2025 <a href="https://www.benzinga.com/general/gaming/24/09/40905542/could-gta-6-be-pushed-to-2026-insights-from-former-rockstar-insider">release window for the game</a>, but Rockstar's silence is testing the patience of even its most loyal fans. 
<figure class="wp-block-embed is-type-rich is-provider-reddit wp-block-embed-reddit"> 
<div class="wp-block-embed__wrapper">
<blockquote class="reddit-embed-bq" style="height:500px" ><a href="https://www.reddit.com/r/GTA6/comments/1gx7j9a/you_are_here/">You are here.</a> by<a href="https://www.reddit.com/user/the123king-reddit/">u/the123king-reddit</a> in<a href="https://www.reddit.com/r/GTA6/">GTA6</a></blockquote>
<script async src="https://embed.reddit.com/widgets.js" charset="UTF-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42046762/the-game-awards-2024-nominees-are-here-dlc-and-remakes-make-the-list">The Game Awards 2024 Nominees Are Here: DLC And Remakes Make The List</a></li>
</ul>
Photo: Shutterstock.

Gaming

TTWO

GTA 6 Trailer 2 Fans Frustrated As Rockstar Possibly Breaks Moon Theory

UBS analyst Joshua Spector downgrades Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) from Buy to Neutral and lowers the price target from $82 to $75.

Downgrades

BERY

UBS Downgrades Berry Global Gr to Neutral, Lowers Price Target to $75

WIIM

Texas Pacific Land shares are trading higher after the company announced it is set to join the S&P 500.

Seaport Global analyst Glenn Chin maintains AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) with a Buy and raises the price target from $180 to $200.

Seaport Global Maintains Buy on AutoNation, Raises Price Target to $200

Seaport Global analyst Glenn Chin maintains Group 1 Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) with a Buy and raises the price target from $400 to $475.

Seaport Global Maintains Buy on Group 1 Automotive, Raises Price Target to $475

The Drug Enforcement Administration (DEA) is facing legal heat following accusations of unlawful communication with Smart Approaches to Marijuana (SAM), a leading opponent of the Biden administration&#8217;s plan to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA). Now, a judge has given both DEA and SAM until November 25 to respond.
Here&#8217;s what we know.
<h3 class="wp-block-heading">The Facts</h3>
On November 20, DEA Administrative Law Judge (ALJ) John Mulrooney issued an order responding to <a href="https://www.benzinga.com/partner/emerging-markets/24/11/42136266/reliance-global-now-adjusted-ebitda-positive-with-growing-revenue-reflecting-potential-b">a motion</a> filed by cannabis organizations Village Farms International and Hemp for Victory. The motion disputes the DEA's role as a "proponent" of the rescheduling rule, alleging conflicts of interest.
The motion argues that the DEA's advocacy for the rescheduling rule violates impartiality principles:
&#8220;Not once in its history as an agency had DEA ever rejected an HHS scheduling recommendation. This time, however, DEA did not just disagree with HHS&#8217;s views, it opposed them so vehemently that the Attorney General had to refer the interagency dispute to the Office of Legal Counsel for resolution.&#8221;
As a result, Mulrooney has set a deadline for the DEA to respond by November 25, 2024. Part of the argument is that the DEA engaged in unlawful communications with the anti-cannabis group SAM, thus indicating its bias on the cannabis issue.
The plot thickened and legal tension escalated the very next day, on November 21, when Mulrooney extended the invitation for SAM to address allegations of unlawful ex parte communications with the DEA.
"As such, it is herein ORDERED, that in addition to the Government, should Smart Approaches to Marijuana (and by this order only that Designated Participant) elect to respond to the Motion it may do so no later than 2:00 P.M. Eastern Time on November 25, 2024,&#8221; stated his last order, as <a href="https://www.marijuanamoment.net/dea-judge-invites-prohibitionist-group-to-explain-allegedly-unlawful-talks-with-agency-amid-marijuana-rescheduling-review/">reported</a> Marijuana Moment.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42093641/dea-is-compromised-doj-should-replace-it-in-cannabis-rescheduling-claims-joint-motion">DEA Is Compromised, DOJ Should Replace It In Cannabis Rescheduling, Claims Joint Motion</a>
<h3 class="wp-block-heading">The Arguments And SAM&#8217;s Alleged Role</h3>
The motion, filed on November 18, claims that the DEA's actions contradict its traditional role. 
The groups argue that the DEA, which enforces controlled substances law, should not also be advocating for changes to that law.
The motion also points out that the DEA's strong opposition to the rescheduling proposal, despite the Department of Health and Human Services (HHS) recommendation, raises concerns about the agency's neutrality. The involvement of SAM in this process, especially regarding alleged unlawful communications, has become a key issue in the case.
That is the reason why Mulrooney has ordered both the DEA and SAM to respond to the allegations, something they have failed to do so far.
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Legal And Political Implications</h3>
As the <a href="https://www.benzinga.com/markets/cannabis/24/08/40567326/dea-delays-cannabis-rescheduling-decision-until-after-november-presidential-election">December 2</a>, hearing approaches, the stakes in this legal battle continue to rise. The outcome could significantly affect cannabis policy in the United States. Cannabis advocates, <a href="https://www.benzinga.com/news/legal/24/11/41923948/dea-faces-lawsuit-alleging-bias-in-marijuana-rescheduling-process">researchers</a> and veterans groups are calling for a fair and transparent process.
These groups have raised concerns about the list of approved participants for the hearing, pointing out that Village Farms is the <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">only cannabis company selected </a>by the DEA. Additionally, despite over <a href="https://www.benzinga.com/markets/cannabis/24/07/39932698/deas-call-for-public-input-on-cannabis-garnered-42-000-comments-majority-want-total-legalization">42,000 public comments</a> supporting rescheduling or delisting cannabis, the DEA's list is dominated by anti-cannabis groups.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">Village Farms Is Only Cannabis Operator Selected To Represent Weed Industry At DEA Rescheduling Hearing</a></li>
</ul>
Cover: AI Generated Image

Cannabis

Legal

DEA Slammed For Unlawful Talks With Cannabis Opponents - The Plot Thickens

Seaport Global analyst Glenn Chin maintains Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) with a Buy and raises the price target from $380 to $450.

Seaport Global Maintains Buy on Lithia Motors, Raises Price Target to $450

Small Cap Consumer Research analyst Eric Beder reiterates Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and maintains $29 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Guess, Maintains $29 Price Target

Seaport Global analyst Glenn Chin maintains Penske Automotive Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAG#NYSE">PAG</a>) with a Buy and raises the price target from $165 to $170.

Seaport Global Maintains Buy on Penske Automotive Group, Raises Price Target to $170

During the last three months, 13 analysts shared their evaluations of Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $201.0, a high estimate of $230.00, and a low estimate of $175.00. This upward trend is apparent, with the current average reflecting a 13.21% increase from the previous average price target of $177.54.
<img src="https://www.benzinga.com/files/images/story/2024/1732298638_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Leidos Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>David Strauss</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Jason Gursky</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Cai von Rumohr</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Ken Herbert</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$180.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$205.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gavin Parsons</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$228.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Peter Arment</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$218.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Jason Gursky</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$194.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Seth Seifman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$183.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Leidos Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Leidos Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Leidos Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LDOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Leidos Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind Leidos Holdings</h2>
Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health markets, both domestically and internationally. Company customer includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in three reportable segments; Defense Solutions, Civil, and Health. Defense Solutions provides technologically latest services, solutions, and products to a broad customer base. It generates key revenue from Defense Solutions.
<h3>Understanding the Numbers: Leidos Holdings's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Leidos Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.86% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.69%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Leidos Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 8.03%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Leidos Holdings's ROA excels beyond industry benchmarks, reaching 2.77%. This signifies efficient management of assets and strong financial health.
Debt Management: Leidos Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.11.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LDOS

Breaking Down Leidos Holdings: 13 Analysts Share Their Views

Analysts' ratings for Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.4, a high estimate of $30.00, and a low estimate of $25.00. Surpassing the previous average price target of $24.88, the current average has increased by 14.15%.
<img src="https://www.benzinga.com/files/images/story/2024/1732298622_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Life Time Group Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>JESALYN Wong</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Rickert</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$28.50</td>
</tr>
<tr>
<td>Michael Hirsh</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Brian Harbour</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Robert Ohmes</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Life Time Group Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Life Time Group Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Life Time Group Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Life Time Group Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Life Time Group Hldgs analyst ratings.</a>
<h2>Delving into Life Time Group Hldgs's Background</h2>
Life Time Group Holdings Inc is a lifestyle brand offering health, fitness and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
<h3>A Deep Dive into Life Time Group Hldgs's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Life Time Group Hldgs's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 18.47%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Life Time Group Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.97% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Life Time Group Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 1.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Life Time Group Hldgs's ROA excels beyond industry benchmarks, reaching 0.58%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.61.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 5 Ratings For Life Time Group Hldgs

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count +1 At 479 Vs 478 Prior; U.S. Baker Hughes NatGas Rig Count -2 At 99 Vs 101 Prior

Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is set to give its latest quarterly earnings report on Monday, 2024-11-25. Here's what investors need to know before the announcement.
Analysts estimate that Grupo Supervielle will report an earnings per share (EPS) of $0.20. 
Investors in Grupo Supervielle are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.11 in the last quarter, leading to a 5.83% increase in the share price on the following day.
Here's a look at Grupo Supervielle's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.11</td>
<td></td>
<td>0.15</td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.22</td>
<td>0.13</td>
<td>0.26</td>
<td>0.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>-6.0%</td>
<td>5.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<h3>Market Performance of Grupo Supervielle's Stock</h3>
Shares of Grupo Supervielle were trading at $10.7 as of November 21. Over the last 52-week period, shares are up 225.54%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SUPV/earnings">To track all earnings releases for Grupo Supervielle visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SUPV

Earnings Preview For Grupo Supervielle

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is set to give its latest quarterly earnings report on Monday, 2024-11-25. Here's what investors need to know before the announcement.
Analysts estimate that Freightos will report an earnings per share (EPS) of $-0.16. 
The announcement from Freightos is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.

<h3>Freightos Share Price Analysis</h3>
Shares of Freightos were trading at $2.4 as of November 21. Over the last 52-week period, shares are down 17.17%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRGO/earnings">To track all earnings releases for Freightos visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGO

A Preview Of Freightos's Earnings

Across the recent three months, 9 analysts have shared their insights on Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $38.67, a high estimate of $55.00, and a low estimate of $27.00. A decline of 10.86% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1732298581_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Endava is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tyler DuPont</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Bryan Bergin</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jonathan Lee</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>James Friedman</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$55.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Jonathan Lee</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Puneet Jain</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Endava. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Endava compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Endava's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Endava's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DAVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Endava analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Endava: A Closer Look</h2>
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the U.K. and it continues to generate the majority of revenue in the U.K. and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
<h3>Unraveling the Financial Story of Endava</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Endava's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 3.52%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Endava's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Endava's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.36%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Endava's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.23%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Endava's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DAVA

Where Endava Stands With Analysts

8 analysts have shared their evaluations of Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.5, a high estimate of $205.00, and a low estimate of $162.00. Surpassing the previous average price target of $176.75, the current average has increased by 2.69%.
<img src="https://www.benzinga.com/files/images/story/2024/1732298574_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Gulfport Energy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$203.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$174.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Zach Parham</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$173.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Zach Parham</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$178.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gulfport Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gulfport Energy compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Gulfport Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gulfport Energy's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GPOR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gulfport Energy analyst ratings.</a>
<h2>Delving into Gulfport Energy's Background</h2>
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition and production of natural gas, crude oil and NGL in the United States. It operates through Utica Shale and Scoop properties. The Utica Shale is located in the Appalachian Basin of the United States and Canada. The Scoop (South Central Oklahoma Oil Province) play of Oklahoma is located in the southeast portion of the prolific Anadarko Basin.
<h3>Key Indicators: Gulfport Energy's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Gulfport Energy's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -4.97%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Gulfport Energy's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -6.97%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gulfport Energy's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.72%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Gulfport Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.47%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GPOR

Analyst Expectations For Gulfport Energy's Future

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp. has enhanced its Board of Directors by appointing Karim...

Medicenna Appoints Industry Veteran to Board

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp., a clinical-stage company specializing in immunotherapy...

Medicenna to Unveil New Immunotherapy Data in Paris

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, is set to enga...

Medicenna Therapeutics Showcases at Global Investment Conference

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp has presented promising preclinical results for two nove...

Medicenna Unveils Groundbreaking Preclinical Therapy Results

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp. successfully held its annual meeting, resulting in the ...

Medicenna Shareholders Show Strong Support at Annual Meeting

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp. will showcase new clinical and preclinical immunotherap...

Medicenna Reveals Key Immunotherapy Data at SITC

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp. has unveiled promising preclinical data from its BiSKIT...

Medicenna Announces Breakthroughs in Cancer Treatment

In a report released today, David Martin PhD from Bloom Burton maintained a Buy rating on Medicenna Therapeutics Corp (MDNA – Research Report), wit...

Promising Clinical Outcomes and Buy Rating for Medicenna Therapeutics' MDNA11

Medicenna Therapeutics Corp (TSE:MDNA) has released an update. Medicenna Therapeutics Corp. has reported promising results from its Phase 1/2 ABILI...

Medicenna Reports Promising Results with MDNA11

Medicenna Therapeutics GAAP EPS of -C$0.05

Press Releases

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference

Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

Medicenna Announces Results of Annual Meeting of Shareholders

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Comments

Medicenna Therapeutics

Medicenna Therapeutics (MDNAF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga